期刊
MULTIPLE SCLEROSIS JOURNAL
卷 19, 期 2, 页码 241-244出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458512444915
关键词
magnetization transfer; multiple sclerosis; alemtuzumab
资金
- Genzyme Corporation
- Bayer Schering Pharma
- Cambridge Biomedical Centre
- UK MS Society
- UCLH/UCL Biomedical Research Centre
- National Institute for Health Research [NF-SI-0508-10058, NF-SI-0508-10335] Funding Source: researchfish
The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (-0.25 pu/year, p < 0.001) and white matter (-0.12 pu/year, p = 0.004). Conversely, mean magnetization transfer ratio was stable in 20 alemtuzumab-treated patients (grey matter: -0.01 pu/year, p = 0.87; white matter: -0.02 pu/year, p = 0.51). The gradient difference in grey matter was 0.25 pu/year < 0.001) after age-adjustment. These data suggest that in multiple sclerosis alemtuzumab protects against tissue damage in normal-appearing grey matter, perhaps by preventing new lesion formation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据